CancerX, a public-private partnership created to boost innovation in the fight against cancer, recently detailed its stakeholders’ work on a “Data Sprint” project. The goal was to identify and prioritize 15 data elements that will form the foundation of a pilot project that will capture and make available the technologies and best practices necessary to accelerate data-driven innovations in cancer research, care, and policy.
CancerX is co-hosted by the Moffitt Cancer Center and Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and the HHS Office of the Assistant Secretary for Health (OASH). Details about the Data Sprint and next steps were discussed at this week’s ONC Annual Meeting.
“By engaging with different stakeholder expertise through diverse collaboratives like CancerX, we're ensuring our data approach is comprehensive, inclusive, and truly beneficial for cancer patients. It's about creating a data ecosystem that is as dynamic and multifaceted as the disease we're fighting against”, said Stephen Konya, senior advisor to the deputy national coordinator, and innovation portfolio lead at ONC, in a statement.
The CancerX Data Sprint convened more than 150 CancerX member organizations from industry and government partners to:
• Identify the high-value research questions that may be asked of the standardized real-world data (RWD) and real-world evidence (RWE) generated by participants through the Enhancing Oncology Model (EOM), and
• Supplement the existing data elements planned for collection through the EOM, with the additional data elements necessary to optimize the RWD/E to support these scientific inquiries.
A CancerX summary of findings said that the Data Sprint successfully demonstrates the potential of digital data strategies, guided by clinical utility and data quality, to produce impactful and comprehensive RWD sets.
It also highlights the power of the public-private partnership model to supplement innovative work advanced by government agencies, collaborating in pursuit of a common goal — specifically, innovation at the intersection of the Center for Medicare & Medicaid Innovation’s EOM, ONC’s U.S. Core Data for Interoperability (USCDI+) - Oncology extension, and other data initiatives across the National Cancer Institute, the U.S. Food and Drug Administration and other groups.
CancerX said that in 2024 stakeholders will have an opportunity to support piloting the implementation of these data elements in coordination with CMMI and ONC, along with EHR vendors, health systems, payers, and data research platforms.
In partnership with member organizations, ASH Research Collaborative, and coordination with government agencies like CMMI and ONC, CancerX can now support an opportunity to pilot the implementation of advanced elements related to real-world datasets captured in multiple myeloma.
The report summary said this would enhance the clinical utility and support EOM/USCDI+ with integration into clinical documentation workflows and studying results through CancerX’s existing site-level and aggregate dashboard infrastructure for broad use by the research community.
